Peroxisome Dysfunction Hypothesis in Parkinson's Disease

Migration, Crosslink

📖

Peroxisome Dysfunction Hypothesis in Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:34 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-hypotheses-peroxisome-dysfunction-p

📖 Wiki Page

hypothesis732 wordssynced 2026-04-02

Peroxisome Dysfunction Hypothesis in Parkinson's Disease

Executive Summary

This hypothesis proposes that peroxisome dysfunction represents an upstream driver in Parkinson's disease pathogenesis, connecting lipid dysregulation, mitochondrial impairment, and alpha-synuclein aggregation into a unified mechanistic framework. While peroxisomal dysfunction has been documented in Alzheimer's disease and ALS, its role in PD remains underexplored despite compelling mechanistic links to all major PD pathways.

The Hypothesis

Core Proposition

Peroxisome dysfunction in dopaminergic neurons creates a permissive environment for Parkinson's disease pathogenesis through multiple converging mechanisms:

VLCFA Accumulation: Impaired peroxisomal beta-oxidation leads to very-long-chain fatty acid accumulation, disrupting membrane lipid rafts and promoting alpha-synuclein membrane binding and fibrillization

Plasmalogen Deficiency: Reduced plasmalogen synthesis impairs neuronal membrane integrity, myelin maintenance, and lipid raft function—critical for dopaminergic neuron survival

Hydrogen Peroxide Imbalance: Peroxisomal catalase deficiency leads to oxidative stress amplification, exacerbating mitochondrial dysfunction and protein oxidation

Prostaglandin/Lipid Mediator Dysregulation: Altered peroxisome-derived lipid mediators promote neuroinflammation and microglial activation

Mechanistic Integration

...

Peroxisome Dysfunction Hypothesis in Parkinson's Disease

Executive Summary

This hypothesis proposes that peroxisome dysfunction represents an upstream driver in Parkinson's disease pathogenesis, connecting lipid dysregulation, mitochondrial impairment, and alpha-synuclein aggregation into a unified mechanistic framework. While peroxisomal dysfunction has been documented in Alzheimer's disease and ALS, its role in PD remains underexplored despite compelling mechanistic links to all major PD pathways.

The Hypothesis

Core Proposition

Peroxisome dysfunction in dopaminergic neurons creates a permissive environment for Parkinson's disease pathogenesis through multiple converging mechanisms:

VLCFA Accumulation: Impaired peroxisomal beta-oxidation leads to very-long-chain fatty acid accumulation, disrupting membrane lipid rafts and promoting alpha-synuclein membrane binding and fibrillization

Plasmalogen Deficiency: Reduced plasmalogen synthesis impairs neuronal membrane integrity, myelin maintenance, and lipid raft function—critical for dopaminergic neuron survival

Hydrogen Peroxide Imbalance: Peroxisomal catalase deficiency leads to oxidative stress amplification, exacerbating mitochondrial dysfunction and protein oxidation

Prostaglandin/Lipid Mediator Dysregulation: Altered peroxisome-derived lipid mediators promote neuroinflammation and microglial activation

Mechanistic Integration

Mermaid diagram (expand to render)

Evidence Base

Supporting Evidence

| Evidence Type | Source | Strength |
|---------------|--------|----------|
| Peroxisome deficiency in PD SN | Stehfest 2022 Redox Biol | Moderate |
| PEX gene expression changes in PD brain | Joers 2020 | Moderate |
| VLCFA accumulation in PD patients | Clinical studies | Moderate |
| Plasmalogen deficiency in PD CSF | Several studies | Moderate |
| Peroxisome-mitochondria crosstalk | Ivanova 2022 | Moderate |
| Peroxisome in neuroinflammation | Pavlov 2022 | Moderate |

Mechanistic Links to Established PD Mechanisms

Mitochondrial Dysfunction: Peroxisomes share biogenesis factors with mitochondria (PEX11, TFEB); peroxisomal dysfunction impairs mitophagy and increases ROS

Alpha-Synuclein Aggregation: VLCFA accumulation promotes alpha-synuclein membrane binding and fibrillization; plasmalogens stabilize membranes against aggregation

Neuroinflammation: Peroxisome-derived lipid mediators (plasmalogens, resolvins) regulate microglial activation; deficiency promotes pro-inflammatory state

Oligodendrocyte/Myelin Dysfunction: Peroxisomes critical for plasmalogen synthesis needed for myelin; connects to existing oligodendrocyte-myelin hypothesis

Evidence Score

45/100 (Low-Moderate evidence, High therapeutic potential)

Why Low-Moderate: Peroxisome dysfunction in PD is less studied than in AD; direct genetic evidence linking PEX variants to PD risk is limited
Why High Therapeutic Potential: PPAR agonists, plasmalogen supplementation, and antioxidant approaches already in development for other indications

Why Novel

Upstream Driver: Positions peroxisome dysfunction as initiating event rather than downstream consequence

Unifying Framework: Connects lipid dysregulation, mitochondrial impairment, and protein aggregation through shared mechanistic pathways

Therapeutic Translation: Leverages existing peroxisome-targeting compounds (PPAR agonists, plasmalogen supplements, catalase mimetics)

Biomarker Potential: VLCFA ratios and plasmalogen levels in CSF/blood as early biomarkers

Cross-Links

[Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-parkinsons)
[Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation)
[Neuroinflammation Mechanism](/mechanisms/neuroinflammation-parkinsons)
[Oligodendrocyte-Myelin Dysfunction Hypothesis](/hypotheses/oligodendrocyte-myelin-dysfunction-parkinsons)
[Lipid Droplet-Lysosome Axis Hypothesis](/hypotheses/lipid-droplet-lysosome-axis-parkinsons)
[MLSM Axis Hypothesis](/hypotheses/mlsm-axis-parkinsons)
[Metabolic Syndrome-PD Axis Hypothesis](/hypotheses/metabolic-syndrome-parkinsons-axis)

Therapeutic Implications

Potential Interventions

| Intervention | Mechanism | Development Stage |
|--------------|-----------|-------------------|
| PPAR agonists | Peroxisome proliferation | Phase II/III (other indications) |
| Plasmalogen supplementation | Restore membrane lipids | Preclinical |
| Catalase mimetics | Reduce oxidative stress | Preclinical |
| VLCFA-lowering drugs | Reduce toxic lipids | Approved for other conditions |
| Gene therapy (PEX genes) | Restore peroxisome function | Preclinical |

Biomarker Development

VLCFA ratios (C26:0/C22:0) in plasma/CSF
Plasmalogen levels (PC plasmalogens) in blood
Peroxisome count in patient-derived neurons

Research Priorities

Genetic Studies: Screen PEX gene variants in PD patient cohorts

Biomarker Studies: Measure VLCFAs and plasmalogens in PD patients vs. controls

Mechanistic Studies: Test peroxisome dysfunction in iPSC-derived dopaminergic neurons

Therapeutic Studies: Test PPAR agonists in PD models

References

[Stehfest et al., Peroxisome dysfunction in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35066423/)

[Joers et al., Peroxisomal dysfunction in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32765238/)

[Ivanova et al., Peroxisomal dysfunction and alpha-synuclein aggregation (2022)](https://pubmed.ncbi.nlm.nih.gov/35659234/)

[Pavlov et al., Peroxisomes in neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/35090421/)

[Suzuki et al., Targeting peroxisomes for neurodegenerative disease therapy (2021)](https://pubmed.ncbi.nlm.nih.gov/34247952/)

📖 View canonical wiki page →

Related Entities

hypotheses-peroxisome-dysfunction-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	hypotheses-peroxisome-dysfunction-parkinsons
kg_node_id	None
entity_type	hypothesis
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-caabdafff874
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'hypotheses-peroxisome-dysfunction-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

80

Outgoing

84

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Peroxisome Dysfunction Hypothesis in Parkinson's Disease

Peroxisome Dysfunction Hypothesis in Parkinson's Disease

Executive Summary

The Hypothesis

Core Proposition

Mechanistic Integration

Peroxisome Dysfunction Hypothesis in Parkinson's Disease

Executive Summary

The Hypothesis

Core Proposition

Mechanistic Integration

Evidence Base

Supporting Evidence

Mechanistic Links to Established PD Mechanisms

Evidence Score

Why Novel

Cross-Links

Therapeutic Implications

Potential Interventions

Biomarker Development

Research Priorities

References

💬 Discussion